Newbury Pharmaceuticals AB (publ) (STO:NEWBRY)
1.035
-0.045 (-4.17%)
At close: Mar 9, 2026
STO:NEWBRY Balance Sheet
Financials in millions SEK. Fiscal year is September - August.
Millions SEK. Fiscal year is Sep - Aug.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '25 Nov 30, 2025 | Aug '25 Aug 31, 2025 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 | Aug '21 Aug 31, 2021 |
| Cash & Equivalents | 7.92 | 14.56 | 15.3 | 8.53 | 33.33 | 13.15 |
| Cash & Short-Term Investments | 7.92 | 14.56 | 15.3 | 8.53 | 33.33 | 13.15 |
| Cash Growth | -59.25% | -4.84% | 79.44% | -74.42% | 153.59% | - |
| Accounts Receivable | - | 7.06 | 15.24 | 9.12 | 0 | 1.08 |
| Other Receivables | 28.57 | 14.17 | 7.01 | 6.39 | 0.79 | 1.25 |
| Receivables | 28.57 | 21.23 | 22.25 | 15.51 | 0.79 | 2.33 |
| Inventory | 9.7 | 9 | 5 | 2.11 | 1.77 | - |
| Prepaid Expenses | - | 1.67 | 1.42 | 1.09 | 0.58 | 0.29 |
| Total Current Assets | 46.19 | 46.46 | 43.97 | 27.24 | 36.47 | 15.77 |
| Goodwill | - | 0.34 | 1.26 | 2.13 | 3.04 | 3.95 |
| Other Intangible Assets | 30.39 | 30.55 | 45.64 | 43.55 | 47.39 | 23.09 |
| Total Assets | 76.58 | 77.35 | 90.87 | 72.92 | 86.91 | 42.81 |
| Accounts Payable | - | 7.32 | 1.94 | 4.28 | 2.04 | 1.88 |
| Accrued Expenses | - | 4.46 | 6.28 | 3.19 | 0.89 | 2.23 |
| Current Income Taxes Payable | - | 0.35 | 0.08 | 0.16 | 0.18 | 0.07 |
| Current Unearned Revenue | - | - | - | 1.63 | - | - |
| Other Current Liabilities | 37.02 | 18.72 | 21.14 | 2.52 | 2.96 | 0.16 |
| Total Current Liabilities | 37.02 | 30.85 | 29.45 | 11.77 | 6.06 | 4.34 |
| Other Long-Term Liabilities | 3.72 | 3.75 | 9.51 | 11.77 | 12.08 | - |
| Total Liabilities | 40.73 | 34.6 | 38.95 | 23.54 | 18.14 | 4.34 |
| Common Stock | 35.85 | 0.97 | 0.77 | 0.62 | 0.62 | 0.16 |
| Additional Paid-In Capital | - | 121.9 | 106.72 | 88.71 | 88.71 | 43.89 |
| Comprehensive Income & Other | - | -80.12 | -55.58 | -39.96 | -20.57 | -5.58 |
| Shareholders' Equity | 35.85 | 42.75 | 51.92 | 49.38 | 68.77 | 38.47 |
| Total Liabilities & Equity | 76.58 | 77.35 | 90.87 | 72.92 | 86.91 | 42.81 |
| Net Cash (Debt) | 7.92 | 14.56 | 15.3 | 8.53 | 33.33 | 13.15 |
| Net Cash Growth | -59.25% | -4.84% | 79.44% | -74.42% | 153.59% | - |
| Net Cash Per Share | 0.29 | 0.56 | 0.71 | 0.44 | 1.87 | - |
| Filing Date Shares Outstanding | 30.4 | 30.4 | 24.26 | 19.52 | 19.52 | 15.68 |
| Total Common Shares Outstanding | 30.4 | 30.4 | 24.26 | 19.52 | 19.52 | 15.68 |
| Working Capital | 9.18 | 15.61 | 14.53 | 15.47 | 30.42 | 11.43 |
| Book Value Per Share | 1.18 | 1.41 | 2.14 | 2.53 | 3.52 | 2.45 |
| Tangible Book Value | 5.46 | 11.87 | 5.02 | 3.7 | 18.34 | 11.43 |
| Tangible Book Value Per Share | 0.18 | 0.39 | 0.21 | 0.19 | 0.94 | 0.73 |
Source: S&P Capital IQ. Standard template. Financial Sources.